GDGuo-Ming Dong

Guo-Ming Dong

*This is an algorithmically generated author record based on publicly available information.

Guo-Ming Dong has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Adili Keranmu

    Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China

    1 shared publication
  • Haitao Niu

    Key Laboratory of Viral Pathogenesis and Infection Prevention and Control (Jinan University), Ministry of Education, School of Medicine, Jinan University, Guangzhou, China

    1 shared publication
  • Hang Yu

    State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

    1 shared publication
  • Hui Xu

    State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China

    1 shared publication
  • Jian-Dong Jiang

    Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

    1 shared publication
  • Jie Fu

    State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

    1 shared publication

Latest Publications

  • Open Access

    Biotransformation of Timosaponin BII into Seven Characteristic Metabolites by the Gut Microbiota

    by Guo-Ming Dong, Hang Yu, Li-Bin Pan, Shu-Rong Ma, Hui Xu, Zheng-Wei Zhang, Pei Han, Jie Fu, Xin-Yu Yang, Adili Keranmu, et al.

    Timosaponin BII is one of the most abundant Anemarrhena saponins and is in a phase II clinical trial for the treatment of dementia. However, the pharmacological activity of timosaponin BII does not match its low bioavailability. In this study, we aimed to determine the effects of gut microbiota on timosaponin BII metabolism. We found that intestinal flora had a strong metabolic effect on timosaponin BII by HPLC-MS/MS. At the same time, seven potential metabolites (M1-M7) produced by rat intestinal flora were identified using HPLC/MS-Q-TOF. Among them, three structures identified are reported in gut microbiota for the first time. A comparison of rat liver homogenate and a rat liver microsome incubation system revealed that the metabolic behavior of timosaponin BII was unique to the gut microbiota system. Finally, a quantitative method for the three representative metabolites was established by HPLC-MS/MS, and the temporal relationship among the metabolites was initially clarified. In summary, it is suggested that the metabolic characteristics of gut microbiota may be an important indicator of the pharmacological activity of timosaponin BII, which can be applied to guide its application and clinical use in the future.